You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The team will use the five-year funding to develop a liquid biopsy-based assay to select and prioritize liver cancer patients who need a liver transplant.
The company announced during its Q4 earnings call that it had acquired Paradigm Diagnostics and Viomics to fill out its expertise in cancer diagnostics.
The firm reported that test volumes for its Cologuard colorectal cancer screening test rose 63 percent year over year.
Research is accumulating for the improved performance of epigenetic signals over mutations, with multiple commercial efforts well underway.
The company released data showing that its panel detects early-stage liver cancer with 71 percent sensitivity compared to 25 percent for the standard test.
The Series A financing will go toward expanding access to its liquid biopsy-based test to more patients in Asia and North America, it said.
In Cell this week: analysis of immune microenvironment in hepatocellular carcinoma, proteogenomic analysis of clear cell renal cell carcinoma, and more.
Although normal tissues with somatic mutations did not necessarily progress to cancer, researchers saw a jump in mutational burden in samples associated with cancer or cirrhosis.
The researchers said the test performed well in distinguishing patients with or without complications and proved itself better than frequently used clinical variables.
Financial analysts seemed convinced of the long-term advantages of the deal but noted that investors may remain skeptical in the near term.
New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.
A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.